尼妥珠单抗联合图像引导放疗治疗老年局部晚期宫颈鳞癌:前瞻性多中心Ⅱ期试验中期分析
该前瞻性、多中心、开放标签、单臂Ⅱ期试验纳入118例≥65岁、未接受化疗的局部晚期宫颈鳞癌患者,给予调强放疗和图像引导近距离放疗联合尼妥珠单抗200 mg每周一次共6周。中位随访24个月,完全缓解率61.86%,客观缓解率91.53%,1年无病生存率92.42%,2年无病生存率84.61%,1年总生存率96.19%,2年总生存率88.22%,常见3级不良事件为白细胞减少等,未记录药物相关严重不良事件或死亡。
要点
- 尼妥珠单抗联合图像引导放疗在老年局部晚期宫颈鳞癌中显示出 promising 的生存获益。
- 完全缓解率61.86%,客观缓解率91.53%,2年无病生存率84.61%,2年总生存率88.22%。
- 常见3级不良事件为白细胞减少、中性粒细胞减少、淋巴细胞减少、贫血和腹泻,未记录药物相关严重不良事件或死亡。
核心结论
- 在老年局部晚期宫颈鳞癌患者中,尼妥珠单抗联合图像引导放疗和近距离放疗耐受性良好,并显示出 promising 的临床生存获益。
研究设计与样本
- 前瞻性、多中心、开放标签、单臂Ⅱ期试验,纳入118例年龄≥65岁、未接受化疗的局部晚期宫颈鳞癌患者。
- 所有患者接受调强放疗和图像引导近距离放疗,尼妥珠单抗200 mg每周一次共6周。
- 主要终点为无病生存期,次要终点包括总生存期、完全缓解率、客观缓解率和安全性。
主要发现
- 中位随访24个月(95% CI: 21.78, 25.53)。
- 完全缓解率61.86%(95% CI: 0.53-0.71),客观缓解率91.53%(95% CI: 0.85-0.96)。
- 1年无病生存率92.42%(95% CI: 85.40-96.14),2年无病生存率84.61%(95% CI: 75.07-90.72),中位无病生存期36.99个月(95% CI: NA, NA)。
- 1年总生存率96.19%(95% CI: 90.15-98.55),2年总生存率88.22%(95% CI: 78.87-93.60),中位总生存期未达到。
- 常见3级不良事件包括白细胞减少(4/30.77%)、中性粒细胞减少(3/23.08%)、淋巴细胞减少(2/15.38%)、腹泻(1/7.69%)和贫血(3/23.08%),未记录药物相关严重不良事件或死亡。
临床怎么用
- 对于≥65岁、未接受化疗的局部晚期宫颈鳞癌患者,可考虑尼妥珠单抗联合图像引导放疗和近距离放疗。
- 治疗期间需关注白细胞减少、中性粒细胞减少、淋巴细胞减少、贫血和腹泻等3级不良事件。
局限性
- 本报道为中期分析,随访时间有限。
- 研究为单臂设计,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Elderly patients with locally advanced cervical squamous cell carcinoma (LACSCC) generally have fewer therapeutic choices. Nimotuzumab, as an epidermal growth factor receptor-targeted humanized monoclonal antibody, has low toxicity, and shown antitumor efficacy in cervical cancer in preliminary study. Therefore, we wanted to explore efficacy and safety of nimotuzumab and image-guided radiation therapy for elderly patients with LACSCC. METHODS AND MATERIALS: This is a prospective, multicenter, open-label, single-arm, and phase II trial. LACSCC patients aged ≥ 65 years not receiving chemotherapy were enrolled. All of the patients received intensity-modulated radiation therapy and image-guided brachytherapy. Nimotuzumab was administration of 200 mg once a week for 6 weeks. Disease-free survival (DFS) is the primary endpoint. Secondary endpoints included overall survival (OS), complete response rate, objective response rate, and safety. RESULTS: From November 2021 to January 2023, a total of 118 elder patients with stage IB3-IVA were enrolled. The median follow-up was 24 months (95% CI: 21.78, 25.53). The complete response rate was 61.86% (95% CI, 0.53-0.71), objective response rate was 91.53% (95% CI, 0.85-0.96). The 1 year-DFS and 2 year-DFS were 92.42% (95% CI, 85.40-96.14) and 84.61% (95% CI, 75.07-90.72), respectively, the median DFS was 36.99 months (95% CI, NA, NA). The 1 year-OS was 96.19% (95% CI, 90.15-98.55), 2 year-OS was 88.22% (95% CI, 78.87-93.60), the median OS was not reached. The most common grade 3 adverse events included leukopenia (4/30.77%), neutropenia (3/23.08%), lymphopenia (2/15.38%), diarrhea (1/7.69%), and anemia (3/23.08%). No drug-related severe adverse events or deaths were recorded. CONCLUSIONS: Among elderly LACSCC patients, nimotuzumab plus image-guided radiation therapy and brachytherapy was well tolerated and indicated promising clinical survival benefits. The robustness of efficacy and toxicity results might provide a novel treatment option for this population.
引用
- Qu A, Zhuo Y, Zhu H, et al. Nimotuzumab Plus Image-Guided Radiation Therapy for Elderly Patients with Locally Advanced Cervical Squamous Cell Carcinoma: Interim Analysis of a Prospective Multicenter Phase II Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41197740. doi:10.1016/j.ijrobp.2025.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。